Efficacy and safety of twice-daily and once-daily olopatadine-mometasone combination nasal spray for seasonal allergic rhinitis

Autor: Dale Mohar, Yacine Salhi, Sudeesh K. Tantry, Charles P. Andrews

Publikováno v: Annals of Allergy, Asthma & Immunology. 124:171-178.e2

GSP301 is an investigational fixed-dose combination nasal spray of olopatadine hydrochloride (antihistamine) and mometasone furoate (corticosteroid).To evaluate efficacy and safety of GSP301 in patients with seasonal AR (SAR).In this phase 2, double-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5ccc9ba5ae7e9d69a361ab67967bf53
https://doi.org/10.1016/j.anai.2019.11.007

Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from Phase 2 and Phase 3 randomized, double-blind, placebo- and active-referenced studies

Autor: Dale Mohar, Bruce G. Martin, Denis Bourrelly, Charles P. Andrews, Frank C. Hampel, Jay van Bavel, Paul H. Ratner, Sara Mangialaio, Parisa Danaietash, Abdel Hmissi, Jasper Dingemanse

Publikováno v: Allergy, Asthma & Clinical Immunology, Vol 13, Iss 1, Pp 1-15 (2017)
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology

Background Antagonism of chemoattractant receptor-homologous molecule on T-helper type-2 cells (CRTH2), a G-protein coupled receptor for prostaglandin D2, could be beneficial for treating allergic disorders. We present findings on the efficacy and sa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e77ad6a736fb458ab7740c99c376cdcf
https://doi.org/10.1186/s13223-017-0183-z

A 26-week Tolerability Study of Ciclesonide Nasal Aerosol in Patients with Perennial Allergic Rhinitis

Autor: Holly Huang, Dale Mohar, William E. Berger, Gordon Raphael, Joseph Hinkle, Craig LaForce, S.Y. Desai

Publikováno v: American Journal of Rhinology & Allergy. 26:302-307

Background A new, hydrofluoroalkane nasal aerosol solution formulation of ciclesonide (CIC-HFA) delivered via a metered dose inhaler is currently in clinical development for treatment of allergic rhinitis. Objective To study tolerability and quality

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97eb70fb0d9421d2498b885b055013e7
https://doi.org/10.2500/ajra.2012.26.3773

OLOPATADINE/MOMETASONE COMBINATION NASAL SPRAY EFFECTIVELY IMPROVES SEASONAL ALLERGIC RHINITIS NASAL SYMPTOMS AND QUALITY OF LIFE

Autor: Dale Mohar, Charles P. Andrews, Sudeesh K. Tantry, Robert L. Jacobs

Publikováno v: Annals of Allergy, Asthma & Immunology. 121:S60

Introduction Seasonal allergic rhinitis (SAR) symptoms are troublesome and may contribute to impaired quality of life (QoL). In a randomized, double-blind phase 2 study, fixed-dose combination of once-daily (QD) or twice-daily (BID) olopatadine hydro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::35984bfd65245219c027fc2883f71c79
https://doi.org/10.1016/j.anai.2018.09.197

Improved quality of life among seasonal allergic rhinitis patients treated with olopatadine HCl nasal spray 0.4% and olopatadine HCl nasal spray 0.6% compared with vehicle placebo

Autor: Frank C. Hampel, Michael J. Brubaker, G. Michael Wall, Julius van Bavel, Niran J. Amar, Margaret Drake, K. Crenshaw, Dale Mohar, Paul H. Ratner, Carol J. Fairchild

Publikováno v: Allergy and Asthma Proceedings. 27:202-207

Seasonal allergic rhinitis (SAR) exerts a significant adverse impact on health-related quality of life (QoL) and productivity of those who suffer from it. Unfortunately, some therapies for SAR also have a negative impact. Therefore, it is important t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58557ef8aab8ce7d5494045788184c6d
https://doi.org/10.2500/aap.2006.27.2862